Literature DB >> 21699921

Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses.

Thomas Hoenen1, Allison Groseth, Fabian de Kok-Mercado, Jens H Kuhn, Victoria Wahl-Jensen.   

Abstract

Reverse-genetics systems are powerful tools enabling researchers to study the replication cycle of RNA viruses, including filoviruses and other hemorrhagic fever viruses, as well as to discover new antivirals. They include full-length clone systems as well as a number of life cycle modeling systems. Full-length clone systems allow for the generation of infectious, recombinant viruses, and thus are an important tool for studying the virus replication cycle in its entirety. In contrast, life cycle modeling systems such as minigenome and transcription and replication competent virus-like particle systems can be used to simulate and dissect parts of the virus life cycle outside of containment facilities. Minigenome systems are used to model viral genome replication and transcription, whereas transcription and replication competent virus-like particle systems also model morphogenesis and budding as well as infection of target cells. As such, these modeling systems have tremendous potential to further the discovery and screening of new antivirals targeting hemorrhagic fever viruses. This review provides an overview of currently established reverse genetics systems for hemorrhagic fever-causing negative-sense RNA viruses, with a particular emphasis on filoviruses, and the potential application of these systems for antiviral research.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21699921      PMCID: PMC3586226          DOI: 10.1016/j.antiviral.2011.06.003

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  122 in total

1.  Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding.

Authors:  Ziying Han; Hani Boshra; J Oriol Sunyer; Susan H Zwiers; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system.

Authors:  Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Rift Valley fever virus.

Authors:  Ramon Flick; Michèle Bouloy
Journal:  Curr Mol Med       Date:  2005-12       Impact factor: 2.222

4.  Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.

Authors:  Jens H Kuhn; Sheli R Radoshitzky; Alexander C Guth; Kelly L Warfield; Wenhui Li; Martin J Vincent; Jonathan S Towner; Stuart T Nichol; Sina Bavari; Hyeryun Choe; M Javad Aman; Michael Farzan
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

5.  Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs.

Authors:  A Bridgen; R M Elliott
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus.

Authors:  A R Carroll; R R Wagner
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

7.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

Authors:  V E Volchkov; H Feldmann; V A Volchkova; H D Klenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

8.  Inhibition of filovirus replication by the zinc finger antiviral protein.

Authors:  Stefanie Müller; Peggy Möller; Matthew J Bick; Stephanie Wurr; Stephan Becker; Stephan Günther; Beate M Kümmerer
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

9.  Rift valley fever virus L protein forms a biologically active oligomer.

Authors:  Aya Zamoto-Niikura; Kaori Terasaki; Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

10.  Infectious defective interfering particles of VSV from transcripts of a cDNA clone.

Authors:  A K Pattnaik; L A Ball; A W LeGrone; G W Wertz
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

View more
  47 in total

1.  Ebola virus VP35 has novel NTPase and helicase-like activities.

Authors:  Ting Shu; Tianyu Gan; Peng Bai; Xiaotong Wang; Qi Qian; Hui Zhou; Qi Cheng; Yang Qiu; Lei Yin; Jin Zhong; Xi Zhou
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

2.  An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.

Authors:  Emily V Nelson; Jennifer R Pacheco; Adam J Hume; Tessa N Cressey; Laure R Deflubé; John B Ruedas; John H Connor; Hideki Ebihara; Elke Mühlberger
Journal:  Antiviral Res       Date:  2017-08-12       Impact factor: 5.970

3.  A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus.

Authors:  Stephanie Devignot; Eric Bergeron; Stuart Nichol; Ali Mirazimi; Friedemann Weber
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

4.  An Improved Reverse Genetics System to Overcome Cell-Type-Dependent Ebola Virus Genome Plasticity.

Authors:  Yoshimi Tsuda; Thomas Hoenen; Logan Banadyga; Carla Weisend; Stacy M Ricklefs; Stephen F Porcella; Hideki Ebihara
Journal:  J Infect Dis       Date:  2015-03-24       Impact factor: 5.226

5.  Inclusion bodies are a site of ebolavirus replication.

Authors:  Thomas Hoenen; Reed S Shabman; Allison Groseth; Astrid Herwig; Michaela Weber; Gordian Schudt; Olga Dolnik; Christopher F Basler; Stephan Becker; Heinz Feldmann
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

6.  Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling.

Authors:  Michaela Weber; Ali Gawanbacht; Matthias Habjan; Andreas Rang; Christoph Borner; Anna Mareike Schmidt; Sophie Veitinger; Ralf Jacob; Stéphanie Devignot; Georg Kochs; Adolfo García-Sastre; Friedemann Weber
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

Review 7.  Development and application of reporter-expressing mononegaviruses: current challenges and perspectives.

Authors:  Darryl Falzarano; Allison Groseth; Thomas Hoenen
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970

8.  High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication.

Authors:  Megan R Edwards; Colette Pietzsch; Thibaut Vausselin; Megan L Shaw; Alexander Bukreyev; Christopher F Basler
Journal:  ACS Infect Dis       Date:  2015-06-24       Impact factor: 5.084

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

10.  A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity.

Authors:  Ari Watt; Felicien Moukambi; Logan Banadyga; Allison Groseth; Julie Callison; Astrid Herwig; Hideki Ebihara; Heinz Feldmann; Thomas Hoenen
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.